Prothena Corp PLC

PRTA

Company Profile

  • Business description

    Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

  • Contact

    77 Sir John Rogerson’s Quay
    Block C
    Grand Canal Docklands
    Dublin 2D02 VK60
    IRL

    T: +353 12362500

    E: [email protected]

    https://www.prothena.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    163

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,902.2523.790.30%
DAX 4024,456.8192.75-0.38%
Dow JONES (US)44,705.19246.890.56%
FTSE 1008,975.66108.641.23%
HKSE24,028.37136.050.57%
NASDAQ20,646.3635.030.17%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,285.1921.930.35%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers